



858828

LEGISLATIVE ACTION

Senate	.	House
Comm: RCS	.	
03/18/2025	.	
	.	
	.	
	.	

The Committee on Criminal Justice (Leek) recommended the following:

1 **Senate Amendment (with directory and title amendments)**

2

3 Delete lines 103 - 1040

4 and insert:

5 37. Xylazine, except for a xylazine animal drug product approved
6 by the United States Food and Drug Administration and the use of
7 which conforms to the approved application or is authorized
8 under 21 U.S.C. s. 360b(a)(4). The manufacture, importation,
9 distribution, prescribing, or sale of xylazine for human use is
10 not subject to this exception.



- 11 38. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine)
12 (Thiophene analog of phencyclidine).
13 39. 3,4,5-Trimethoxyamphetamine.
14 40. Methylone (3,4-Methylenedioxymethcathinone).
15 41. MDPV (3,4-Methylenedioxypyrovalerone).
16 42. Methylmethcathinone.
17 43. Methoxymethcathinone.
18 44. Fluoromethcathinone.
19 45. Methylethcathinone.
20 46. CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-
21 yl)phenol) and its dimethyloctyl (C8) homologue.
22 47. HU-210 [(6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-(2-
23 methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol].
24 48. JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
25 49. JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
26 50. JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-
27 naphthoyl)indole).
28 51. BZP (Benzylpiperazine).
29 52. Fluorophenylpiperazine.
30 53. Methylphenylpiperazine.
31 54. Chlorophenylpiperazine.
32 55. Methoxyphenylpiperazine.
33 56. DBZP (1,4-Dibenzylpiperazine).
34 57. TFMPP (Trifluoromethylphenylpiperazine).
35 58. MBDB (Methylbenzodioxolylbutanamine) or (3,4-
36 Methylenedioxy-N-methylbutanamine).
37 59. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine).
38 60. 5-Hydroxy-N-methyltryptamine.
39 61. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine).



- 40 62. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine).
41 63. Methyltryptamine.
42 64. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine).
43 65. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine).
44 66. Tyramine (4-Hydroxyphenethylamine).
45 67. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine).
46 68. DiPT (N,N-Diisopropyltryptamine).
47 69. DPT (N,N-Dipropyltryptamine).
48 70. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine).
49 71. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine).
50 72. DOI (4-Iodo-2,5-dimethoxyamphetamine).
51 73. DOC (4-Chloro-2,5-dimethoxyamphetamine).
52 74. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
53 75. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
54 76. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
55 77. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
56 78. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
57 79. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
58 80. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
59 81. Butylone (3,4-Methylenedioxy-alpha-
60 methylaminobutyrophenone).
61 82. Ethcathinone.
62 83. Ethylone (3,4-Methylenedioxy-N-ethylcathinone).
63 84. Naphyrone (Naphthylpyrovalerone).
64 85. Dimethylone (3,4-Methylenedioxy-N,N-dimethylcathinone).
65 86. 3,4-Methylenedioxy-N,N-diethylcathinone.
66 87. 3,4-Methylenedioxy-propiophenone.
67 88. 3,4-Methylenedioxy-alpha-bromopropiophenone.
68 89. 3,4-Methylenedioxy-propiophenone-2-oxime.



858828

- 69 90. 3,4-Methylenedioxy-N-acetylcathinone.
70 91. 3,4-Methylenedioxy-N-acetylmethcathinone.
71 92. 3,4-Methylenedioxy-N-acetylethcathinone.
72 93. Bromomethcathinone.
73 94. Buphedrone (alpha-Methylamino-butyrophenone).
74 95. Eutylone (3,4-Methylenedioxy-alpha-
75 ethylaminobutyrophenone).
76 96. Dimethylcathinone.
77 97. Dimethylmethcathinone.
78 98. Pentylone (3,4-Methylenedioxy-alpha-
79 methylaminovalerophenone).
80 99. MDPPP (3,4-Methylenedioxy-alpha-
81 pyrrolidinopropiophenone).
82 100. MDPBP (3,4-Methylenedioxy-alpha-
83 pyrrolidinobutyrophenone).
84 101. MOPPP (Methoxy-alpha-pyrrolidinopropiophenone).
85 102. MPHP (Methyl-alpha-pyrrolidinohexanophenone).
86 103. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP
87 (Benocyclidine).
88 104. F-MABP (Fluoromethylaminobutyrophenone).
89 105. MeO-PBP (Methoxypyrrolidinobutyrophenone).
90 106. Et-PBP (Ethylpyrrolidinobutyrophenone).
91 107. 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone).
92 108. Me-EABP (Methylethylaminobutyrophenone).
93 109. Etizolam.
94 110. PPP (Pyrrolidinopropiophenone).
95 111. PBP (Pyrrolidinobutyrophenone).
96 112. PVP (Pyrrolidinovalerophenone) or
97 (Pyrrolidinopentiophenone).



- 98 113. MPPP (Methyl-alpha-pyrrolidinopropiophenone) .
99 114. JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole) .
100 115. JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole) .
101 116. JWH-019 (1-Hexyl-3-(1-naphthoyl)indole) .
102 117. JWH-020 (1-Heptyl-3-(1-naphthoyl)indole) .
103 118. JWH-072 (1-Propyl-3-(1-naphthoyl)indole) .
104 119. JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole) .
105 120. JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole) .
106 121. JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan-
107 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene) .
108 122. JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole) .
109 123. JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole) .
110 124. JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole) .
111 125. JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole) .
112 126. JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) .
113 127. JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole) .
114 128. JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole) .
115 129. JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole) .
116 130. HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-
117 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-
118 ol) .
119 131. HU-308 (((1R,2R,5R)-2-[2,6-Dimethoxy-4-(2-methyloctan-
120 2-yl)phenyl]-7,7-dimethyl-4-bicyclo[3.1.1]hept-3-enyl]
121 methanol) .
122 132. HU-331 (3-Hydroxy-2-[(1R,6R)-3-methyl-6-(1-
123 methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-2,5-cyclohexadiene-
124 1,4-dione) .
125 133. CB-13 (4-Pentyloxy-1-(1-naphthoyl)naphthalene) .
126 134. CB-25 (N-Cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)-



- 127 undecanamide) .
128 135. CB-52 (N-Cyclopropyl-11-(2-hexyl-5-hydroxyphenoxy)-
129 undecanamide) .
130 136. CP 55,940 (2-[3-Hydroxy-6-propanol-cyclohexyl]-5-(2-
131 methyloctan-2-yl)phenol) .
132 137. AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole) .
133 138. AM-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indole) .
134 139. RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole) .
135 140. RCS-8 (1-(2-Cyclohexylethyl)-3-(2-
136 methoxyphenylacetyl)indole) .
137 141. WIN55,212-2 ((R)-(+)-[2,3-Dihydro-5-methyl-3-(4-
138 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
139 naphthalenylmethanone) .
140 142. WIN55,212-3 [(3S)-2,3-Dihydro-5-methyl-3-(4-
141 morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
142 naphthalenylmethanone) .
143 143. Pentedrone (alpha-Methylaminovalerophenone) .
144 144. Fluoroamphetamine.
145 145. Fluoromethamphetamine.
146 146. Methoxetamine.
147 147. Methiopropamine.
148 148. Methylbuphedrone (Methyl-alpha-
149 methylaminobutyrophenone) .
150 149. APB ((2-Aminopropyl)benzofuran) .
151 150. APDB ((2-Aminopropyl)-2,3-dihydrobenzofuran) .
152 151. UR-144 (1-Pentyl-3-(2,2,3,3-
153 tetramethylcyclopropanoyl)indole) .
154 152. XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3-
155 tetramethylcyclopropanoyl)indole) .



- 156 153. Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3-tetramethylcyclopropanoyl)indole).
- 157
- 158 154. AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).
- 159 155. AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-iodobenzoyl)indole).
- 160
- 161 156. STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3-carboxamide).
- 162
- 163 157. URB-597 ((3'-(Aminocarbonyl)[1,1'-biphenyl]-3-yl)-cyclohexylcarbamate).
- 164
- 165 158. URB-602 ([1,1'-Biphenyl]-3-yl-carbamic acid, cyclohexyl ester).
- 166
- 167 159. URB-754 (6-Methyl-2-[(4-methylphenyl)amino]-1-benzoxazin-4-one).
- 168
- 169 160. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
- 170
- 171 161. 2C-H (2,5-Dimethoxyphenethylamine).
- 172
- 173 162. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine).
- 174 163. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine).
- 175
- 176 164. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2-methoxybenzyl)]phenethylamine).
- 177
- 178 165. MDMA (3,4-Methylenedioxymethamphetamine).
- 179
- 180 166. PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).
- 181
- 182 167. Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3-carboxylate).
- 183
- 184 168. BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3-carboxylate).
169. Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole-3-carboxamide).
170. AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentylindazole-3-carboxamide).



858828

- 185 171. AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
186 (4-fluorobenzyl)indazole-3-carboxamide).
187 172. ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-
188 1-pentylindeazole-3-carboxamide).
189 173. Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-
190 yl)-1-(fluoropentyl)indole-3-carboxamide).
191 174. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2-
192 methoxybenzyl)phenethylamine].
193 175. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2-
194 methoxybenzyl)phenethylamine].
195 176. AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
196 (cyclohexylmethyl)indazole-3-carboxamide).
197 177. FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3-
198 carboxylate).
199 178. Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole-
200 3-carboxamide).
201 179. Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-
202 (fluoropentyl)indazole-3-carboxamide).
203 180. THJ-2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl)indazole).
204 181. AM-855 ((4aR,12bR)-8-Hexyl-2,5,5-trimethyl-
205 1,4,4a,8,9,10,11,12b-octahydronaphtho[3,2-c]isochromen-12-ol).
206 182. AM-905 ((6aR,9R,10aR)-3-[(E)-Hept-1-enyl]-9-
207 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-
208 hexahydrobenzo[c]chromen-1-ol).
209 183. AM-906 ((6aR,9R,10aR)-3-[(Z)-Hept-1-enyl]-9-
210 (hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-
211 hexahydrobenzo[c]chromen-1-ol).
212 184. AM-2389 ((6aR,9R,10aR)-3-(1-Hexyl-cyclobut-1-yl)-
213 6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-6H-dibenzo[b,d]pyran-1,9



858828

214 diol).

215 185. HU-243 ((6aR,8S,9S,10aR)-9-(Hydroxymethyl)-6,6-

216 dimethyl-3-(2-methyloctan-2-yl)-8,9-ditritio-7,8,10,10a-

217 tetrahydro-6aH-benzo[c]chromen-1-ol).

218 186. HU-336 ((6aR,10aR)-6,6,9-Trimethyl-3-pentyl-

219 6a,7,10,10a-tetrahydro-1H-benzo[c]chromene-1,4(6H)-dione).

220 187. MAPB ((2-Methylaminopropyl)benzofuran).

221 188. 5-IT (2-(1H-Indol-5-yl)-1-methyl-ethylamine).

222 189. 6-IT (2-(1H-Indol-6-yl)-1-methyl-ethylamine).

223 190. Synthetic Cannabinoids.—Unless specifically excepted

224 or unless listed in another schedule or contained within a

225 pharmaceutical product approved by the United States Food and

226 Drug Administration, any material, compound, mixture, or

227 preparation that contains any quantity of a synthetic

228 cannabinoid found to be in any of the following chemical class

229 descriptions, or homologues, nitrogen-heterocyclic analogs,

230 isomers (including optical, positional, or geometric), esters,

231 ethers, salts, and salts of homologues, nitrogen-heterocyclic

232 analogs, isomers, esters, or ethers, whenever the existence of

233 such homologues, nitrogen-heterocyclic analogs, isomers, esters,

234 ethers, salts, and salts of isomers, esters, or ethers is

235 possible within the specific chemical class or designation.

236 Since nomenclature of these synthetically produced cannabinoids

237 is not internationally standardized and may continually evolve,

238 these structures or the compounds of these structures shall be

239 included under this subparagraph, regardless of their specific

240 numerical designation of atomic positions covered, if it can be

241 determined through a recognized method of scientific testing or

242 analysis that the substance contains properties that fit within



858828

243 one or more of the following categories:

244 a. Tetrahydrocannabinols.—Any tetrahydrocannabinols
245 naturally contained in a plant of the genus *Cannabis*, the
246 synthetic equivalents of the substances contained in the plant
247 or in the resinous extracts of the genus *Cannabis*, or synthetic
248 substances, derivatives, and their isomers with similar chemical
249 structure and pharmacological activity, including, but not
250 limited to, Delta 9 tetrahydrocannabinols and their optical
251 isomers, Delta 8 tetrahydrocannabinols and their optical
252 isomers, Delta 6a,10a tetrahydrocannabinols and their optical
253 isomers, or any compound containing a tetrahydrobenzo[c]chromene
254 structure with substitution at either or both the 3-position or
255 9-position, with or without substitution at the 1-position with
256 hydroxyl or alkoxy groups, including, but not limited to:

257 (I) Tetrahydrocannabinol.

258 (II) HU-210 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-
259 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-
260 ol).

261 (III) HU-211 ((6aS,10aS)-9-(Hydroxymethyl)-6,6-dimethyl-3-
262 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-
263 ol).

264 (IV) JWH-051 ((6aR,10aR)-9-(Hydroxymethyl)-6,6-dimethyl-3-
265 (2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

266 (V) JWH-133 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methylpentan-
267 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

268 (VI) JWH-057 ((6aR,10aR)-6,6,9-Trimethyl-3-(2-methyloctan-
269 2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).

270 (VII) JWH-359 ((6aR,10aR)-1-Methoxy-6,6,9-trimethyl-3-(2,3-
271 dimethylpentan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromene).



858828

272 (VIII) AM-087 ((6aR,10aR)-3-(2-Methyl-6-bromohex-2-yl)-
273 6,6,9-trimethyl-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
274 (IX) AM-411 ((6aR,10aR)-3-(1-Adamantyl)-6,6,9-trimethyl-
275 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol).
276 (X) Parahexyl.
277 b. Naphthoylindoles, Naphthoylindazoles,
278 Naphthoylcarbazoles, Naphthylmethylindoles,
279 Naphthylmethylindazoles, and Naphthylmethylcarbazoles.—Any
280 compound containing a naphthoylindole, naphthoylindazole,
281 naphthoylcarbazole, naphthylmethylindole,
282 naphthylmethylindazole, or naphthylmethylcarbazole structure,
283 with or without substitution on the indole, indazole, or
284 carbazole ring to any extent, whether or not substituted on the
285 naphthyl ring to any extent, including, but not limited to:
286 (I) JWH-007 (1-Pentyl-2-methyl-3-(1-naphthoyl)indole).
287 (II) JWH-011 (1-(1-Methylhexyl)-2-methyl-3-(1-
288 naphthoyl)indole).
289 (III) JWH-015 (1-Propyl-2-methyl-3-(1-naphthoyl)indole).
290 (IV) JWH-016 (1-Butyl-2-methyl-3-(1-naphthoyl)indole).
291 (V) JWH-018 (1-Pentyl-3-(1-naphthoyl)indole).
292 (VI) JWH-019 (1-Hexyl-3-(1-naphthoyl)indole).
293 (VII) JWH-020 (1-Heptyl-3-(1-naphthoyl)indole).
294 (VIII) JWH-022 (1-(4-Pentenyl)-3-(1-naphthoyl)indole).
295 (IX) JWH-071 (1-Ethyl-3-(1-naphthoyl)indole).
296 (X) JWH-072 (1-Propyl-3-(1-naphthoyl)indole).
297 (XI) JWH-073 (1-Butyl-3-(1-naphthoyl)indole).
298 (XII) JWH-080 (1-Butyl-3-(4-methoxy-1-naphthoyl)indole).
299 (XIII) JWH-081 (1-Pentyl-3-(4-methoxy-1-naphthoyl)indole).
300 (XIV) JWH-098 (1-Pentyl-2-methyl-3-(4-methoxy-1-



301 naphthoyl) indole).
302 (XV) JWH-116 (1-Pentyl-2-ethyl-3-(1-naphthoyl)indole).
303 (XVI) JWH-122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole).
304 (XVII) JWH-149 (1-Pentyl-2-methyl-3-(4-methyl-1-
305 naphthoyl) indole).
306 (XVIII) JWH-164 (1-Pentyl-3-(7-methoxy-1-naphthoyl)indole).
307 (XIX) JWH-175 (1-Pentyl-3-(1-naphthylmethyl)indole).
308 (XX) JWH-180 (1-Propyl-3-(4-propyl-1-naphthoyl)indole).
309 (XXI) JWH-182 (1-Pentyl-3-(4-propyl-1-naphthoyl)indole).
310 (XXII) JWH-184 (1-Pentyl-3-[(4-methyl)-1-
311 naphthylmethyl]indole).
312 (XXIII) JWH-193 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methyl-1-
313 naphthoyl)indole).
314 (XXIV) JWH-198 (1-[2-(4-Morpholinyl)ethyl]-3-(4-methoxy-1-
315 naphthoyl)indole).
316 (XXV) JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-
317 naphthoyl)indole).
318 (XXVI) JWH-210 (1-Pentyl-3-(4-ethyl-1-naphthoyl)indole).
319 (XXVII) JWH-387 (1-Pentyl-3-(4-bromo-1-naphthoyl)indole).
320 (XXVIII) JWH-398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole).
321 (XXIX) JWH-412 (1-Pentyl-3-(4-fluoro-1-naphthoyl)indole).
322 (XXX) JWH-424 (1-Pentyl-3-(8-bromo-1-naphthoyl)indole).
323 (XXXI) AM-1220 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(1-
324 naphthoyl)indole).
325 (XXXII) AM-1235 (1-(5-Fluoropentyl)-6-nitro-3-(1-
326 naphthoyl)indole).
327 (XXXIII) AM-2201 (1-(5-Fluoropentyl)-3-(1-
328 naphthoyl)indole).
329 (XXXIV) Chloro JWH-018 (1-(Chloropentyl)-3-(1-



858828

330 naphthoyl) indole).
331 (XXXV) Bromo JWH-018 (1-(Bromopentyl)-3-(1-
332 naphthoyl) indole).
333 (XXXVI) AM-2232 (1-(4-Cyanobutyl)-3-(1-naphthoyl) indole).
334 (XXXVII) THJ-2201 (1-(5-Fluoropentyl)-3-(1-
335 naphthoyl) indazole).
336 (XXXVIII) MAM-2201 (1-(5-Fluoropentyl)-3-(4-methyl-1-
337 naphthoyl) indole).
338 (XXXIX) EAM-2201 (1-(5-Fluoropentyl)-3-(4-ethyl-1-
339 naphthoyl) indole).
340 (XL) EG-018 (9-Pentyl-3-(1-naphthoyl) carbazole).
341 (XLI) EG-2201 (9-(5-Fluoropentyl)-3-(1-
342 naphthoyl) carbazole).
343 c. Naphthoylpyrroles.—Any compound containing a
344 naphthoylpyrrole structure, with or without substitution on the
345 pyrrole ring to any extent, whether or not substituted on the
346 naphthyl ring to any extent, including, but not limited to:
347 (I) JWH-030 (1-Pentyl-3-(1-naphthoyl) pyrrole).
348 (II) JWH-031 (1-Hexyl-3-(1-naphthoyl) pyrrole).
349 (III) JWH-145 (1-Pentyl-5-phenyl-3-(1-naphthoyl) pyrrole).
350 (IV) JWH-146 (1-Heptyl-5-phenyl-3-(1-naphthoyl) pyrrole).
351 (V) JWH-147 (1-Hexyl-5-phenyl-3-(1-naphthoyl) pyrrole).
352 (VI) JWH-307 (1-Pentyl-5-(2-fluorophenyl)-3-(1-
353 naphthoyl) pyrrole).
354 (VII) JWH-309 (1-Pentyl-5-(1-naphthalenyl)-3-(1-
355 naphthoyl) pyrrole).
356 (VIII) JWH-368 (1-Pentyl-5-(3-fluorophenyl)-3-(1-
357 naphthoyl) pyrrole).
358 (IX) JWH-369 (1-Pentyl-5-(2-chlorophenyl)-3-(1-



858828

359 naphthoyl)pyrrole).

360 (X) JWH-370 (1-Pentyl-5-(2-methylphenyl)-3-(1-
361 naphthoyl)pyrrole).

362 d. Naphthylmethylenindenes.—Any compound containing a
363 naphthylmethylenindene structure, with or without substitution
364 at the 3-position of the indene ring to any extent, whether or
365 not substituted on the naphthyl ring to any extent, including,
366 but not limited to, JWH-176 (3-Pentyl-1-
367 (naphthylmethylene)indene).

368 e. Phenylacetylindoles and Phenylacetylindazoles.—Any
369 compound containing a phenylacetylindole or phenylacetylindazole
370 structure, with or without substitution on the indole or
371 indazole ring to any extent, whether or not substituted on the
372 phenyl ring to any extent, including, but not limited to:

373 (I) JWH-167 (1-Pentyl-3-(phenylacetyl)indole).

374 (II) JWH-201 (1-Pentyl-3-(4-methoxyphenylacetyl)indole).

375 (III) JWH-203 (1-Pentyl-3-(2-chlorophenylacetyl)indole).

376 (IV) JWH-250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole).

377 (V) JWH-251 (1-Pentyl-3-(2-methylphenylacetyl)indole).

378 (VI) JWH-302 (1-Pentyl-3-(3-methoxyphenylacetyl)indole).

379 (VII) Cannabipiperidiethanone.

380 (VIII) RCS-8 (1-(2-Cyclohexylethyl)-3-(2-
381 methoxyphenylacetyl)indole).

382 f. Cyclohexylphenols.—Any compound containing a
383 cyclohexylphenol structure, with or without substitution at the
384 5-position of the phenolic ring to any extent, whether or not
385 substituted on the cyclohexyl ring to any extent, including, but
386 not limited to:

387 (I) CP 47,497 (2-(3-Hydroxycyclohexyl)-5-(2-methyloctan-2-



858828

388 yl)phenol).

389 (II) Cannabicyclohexanol (CP 47,497 dimethyloctyl (C8)

390 homologue).

391 (III) CP-55,940 (2-(3-Hydroxy-6-propanol-cyclohexyl)-5-(2-

392 methyloctan-2-yl)phenol).

393 g. Benzoylindoles and Benzoylindazoles.—Any compound

394 containing a benzoylindole or benzoylindazole structure, with or

395 without substitution on the indole or indazole ring to any

396 extent, whether or not substituted on the phenyl ring to any

397 extent, including, but not limited to:

398 (I) AM-679 (1-Pentyl-3-(2-iodobenzoyl)indole).

399 (II) AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole).

400 (III) AM-1241 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-

401 iodo-5-nitrobenzoyl)indole).

402 (IV) Pravadoline (1-[2-(4-Morpholinyl)ethyl]-2-methyl-3-(4-

403 methoxybenzoyl)indole).

404 (V) AM-2233 (1-[(N-Methyl-2-piperidinyl)methyl]-3-(2-

405 iodobenzoyl)indole).

406 (VI) RCS-4 (1-Pentyl-3-(4-methoxybenzoyl)indole).

407 (VII) RCS-4 C4 homologue (1-Butyl-3-(4-

408 methoxybenzoyl)indole).

409 (VIII) AM-630 (1-[2-(4-Morpholinyl)ethyl]-2-methyl-6-iodo-

410 3-(4-methoxybenzoyl)indole).

411 h. Tetramethylcyclopropanoylindoles and

412 Tetramethylcyclopropanoylindazoles.—Any compound containing a

413 tetramethylcyclopropanoylindole or

414 tetramethylcyclopropanoylindazole structure, with or without

415 substitution on the indole or indazole ring to any extent,

416 whether or not substituted on the tetramethylcyclopropyl group



858828

417 to any extent, including, but not limited to:

418 (I) UR-144 (1-Pentyl-3-(2,2,3,3-

419 tetramethylcyclopropanoyl)indole).

420 (II) XLR11 (1-(5-Fluoropentyl)-3-(2,2,3,3-

421 tetramethylcyclopropanoyl)indole).

422 (III) Chloro UR-144 (1-(Chloropentyl)-3-(2,2,3,3-

423 tetramethylcyclopropanoyl)indole).

424 (IV) A-796,260 (1-[2-(4-Morpholinyl)ethyl]-3-(2,2,3,3-

425 tetramethylcyclopropanoyl)indole).

426 (V) A-834,735 (1-[4-(Tetrahydropyranyl)methyl]-3-(2,2,3,3-

427 tetramethylcyclopropanoyl)indole).

428 (VI) M-144 (1-(5-Fluoropentyl)-2-methyl-3-(2,2,3,3-

429 tetramethylcyclopropanoyl)indole).

430 (VII) FUB-144 (1-(4-Fluorobenzyl)-3-(2,2,3,3-

431 tetramethylcyclopropanoyl)indole).

432 (VIII) FAB-144 (1-(5-Fluoropentyl)-3-(2,2,3,3-

433 tetramethylcyclopropanoyl)indazole).

434 (IX) XLR12 (1-(4,4,4-Trifluorobutyl)-3-(2,2,3,3-

435 tetramethylcyclopropanoyl)indole).

436 (X) AB-005 (1-[(1-Methyl-2-piperidinyl)methyl]-3-(2,2,3,3-

437 tetramethylcyclopropanoyl)indole).

438 i. Adamantoylindoles, Adamantoylindazoles, Adamantylindole

439 carboxamides, and Adamantylindazole carboxamides.—Any compound

440 containing an adamantoyl indole, adamantoyl indazole, adamantlyl

441 indole carboxamide, or adamantlyl indazole carboxamide structure,

442 with or without substitution on the indole or indazole ring to

443 any extent, whether or not substituted on the adamantlyl ring to

444 any extent, including, but not limited to:

445 (I) AKB48 (N-Adamant-1-yl 1-pentylindazole-3-carboxamide).



858828

446 (II) Fluoro AKB48 (N-Adamant-1-yl 1-(fluoropentyl)indazole-
447 3-carboxamide).

448 (III) STS-135 (N-Adamant-1-yl 1-(5-fluoropentyl)indole-3-
449 carboxamide).

450 (IV) AM-1248 (1-(1-Methylpiperidine)methyl-3-(1-
451 adamantoyl)indole).

452 (V) AB-001 (1-Pentyl-3-(1-adamantoyl)indole).

453 (VI) APICA (N-Adamant-1-yl 1-pentylindole-3-carboxamide).

454 (VII) Fluoro AB-001 (1-(Fluoropentyl)-3-(1-
455 adamantoyl)indole).

456 j. Quinolinylindolecarboxylates,

457 Quinolinylindolecarboxylates, Quinolinylindolecarboxamides,
458 and Quinolinylindolecarboxamides.—Any compound containing a
459 quinolinylindole carboxylate, quinolinylindazole carboxylate,
460 isoquinolinylindole carboxylate, isoquinolinylindazole
461 carboxylate, quinolinylindole carboxamide, quinolinylindazole
462 carboxamide, isoquinolinylindole carboxamide, or
463 isoquinolinylindazole carboxamide structure, with or without
464 substitution on the indole or indazole ring to any extent,
465 whether or not substituted on the quinoline or isoquinoline ring
466 to any extent, including, but not limited to:

467 (I) PB-22 (8-Quinolinyl 1-pentylindole-3-carboxylate).

468 (II) Fluoro PB-22 (8-Quinolinyl 1-(fluoropentyl)indole-3-
469 carboxylate).

470 (III) BB-22 (8-Quinolinyl 1-(cyclohexylmethyl)indole-3-
471 carboxylate).

472 (IV) FUB-PB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indole-3-
473 carboxylate).

474 (V) NPB-22 (8-Quinolinyl 1-pentylindazole-3-carboxylate).



858828

475 (VI) Fluoro NPB-22 (8-Quinolinyl 1-(fluoropentyl)indazole-
476 3-carboxylate).

477 (VII) FUB-NPB-22 (8-Quinolinyl 1-(4-fluorobenzyl)indazole-
478 3-carboxylate).

479 (VIII) THJ (8-Quinolinyl 1-pentylindazole-3-carboxamide).

480 (IX) Fluoro THJ (8-Quinolinyl 1-(fluoropentyl)indazole-3-
481 carboxamide).

482 k. Naphthylindolecarboxylates and
483 Naphthylindazolecarboxylates.—Any compound containing a
484 naphthylindole carboxylate or naphthylindazole carboxylate
485 structure, with or without substitution on the indole or
486 indazole ring to any extent, whether or not substituted on the
487 naphthyl ring to any extent, including, but not limited to:

488 (I) NM-2201 (1-Naphthalenyl 1-(5-fluoropentyl)indole-3-
489 carboxylate).

490 (II) SDB-005 (1-Naphthalenyl 1-pentylindazole-3-
491 carboxylate).

492 (III) Fluoro SDB-005 (1-Naphthalenyl 1-
493 (fluoropentyl)indazole-3-carboxylate).

494 (IV) FDU-PB-22 (1-Naphthalenyl 1-(4-fluorobenzyl)indole-3-
495 carboxylate).

496 (V) 3-CAF (2-Naphthalenyl 1-(2-fluorophenyl)indazole-3-
497 carboxylate).

498 1. Naphthylindole carboxamides and Naphthylindazole
499 carboxamides.—Any compound containing a naphthylindole
500 carboxamide or naphthylindazole carboxamide structure, with or
501 without substitution on the indole or indazole ring to any
502 extent, whether or not substituted on the naphthyl ring to any
503 extent, including, but not limited to:



858828

- 504 (I) NNEI (N-Naphthalen-1-yl 1-pentylindole-3-carboxamide).
505 (II) Fluoro-NNEI (N-Naphthalen-1-yl 1-(fluoropentyl)indole-
506 3-carboxamide).
507 (III) Chloro-NNEI (N-Naphthalen-1-yl 1-
508 (chloropentyl)indole-3-carboxamide).
509 (IV) MN-18 (N-Naphthalen-1-yl 1-pentylindazole-3-
510 carboxamide).
511 (V) Fluoro MN-18 (N-Naphthalen-1-yl 1-
512 (fluoropentyl)indazole-3-carboxamide).
513 m. Alkylcarbonyl indole carboxamides, Alkylcarbonyl
514 indazole carboxamides, Alkylcarbonyl indole carboxylates, and
515 Alkylcarbonyl indazole carboxylates.—Any compound containing an
516 alkylcarbonyl group, including 1-amino-3-methyl-1-oxobutan-2-yl,
517 1-methoxy-3-methyl-1-oxobutan-2-yl, 1-amino-1-oxo-3-
518 phenylpropan-2-yl, 1-methoxy-1-oxo-3-phenylpropan-2-yl, with an
519 indole carboxamide, indazole carboxamide, indole carboxylate, or
520 indazole carboxylate, with or without substitution on the indole
521 or indazole ring to any extent, whether or not substituted on
522 the alkylcarbonyl group to any extent, including, but not
523 limited to:
524 (I) ADBICA, (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
525 pentylindole-3-carboxamide).
526 (II) Fluoro ADBICA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-
527 yl)-1-(fluoropentyl)indole-3-carboxamide).
528 (III) Fluoro ABICA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
529 (fluoropentyl)indole-3-carboxamide).
530 (IV) AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
531 pentylindazole-3-carboxamide).
532 (V) Fluoro AB-PINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-



858828

533 1-(fluoropentyl)indazole-3-carboxamide).
534 (VI) ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-
535 1-pentylinidazole-3-carboxamide).
536 (VII) Fluoro ADB-PINACA (N-(1-Amino-3,3-dimethyl-1-
537 oxobutan-2-yl)-1-(fluoropentyl)indazole-3-carboxamide).
538 (VIII) AB-FUBINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
539 (4-fluorobenzyl)indazole-3-carboxamide).
540 (IX) ADB-FUBINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-
541 yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
542 (X) AB-CHMINACA (N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-
543 (cyclohexylmethyl)indazole-3-carboxamide).
544 (XI) MA-CHMINACA (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-
545 (cyclohexylmethyl)indazole-3-carboxamide).
546 (XII) MAB-CHMINACA (N-(1-Amino-3,3-dimethyl-1-oxobutan-2-
547 yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
548 (XIII) AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-
549 pentylinidazole-3-carboxamide).
550 (XIV) Fluoro-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-
551 (fluoropentyl)indazole-3-carboxamide).
552 (XV) FUB-AMB (N-(1-Methoxy-3-methyl-1-oxobutan-2-yl)-1-(4-
553 fluorobenzyl)indazole-3-carboxamide).
554 (XVI) MDMB-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-
555 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide).
556 (XVII) MDMB-FUBINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-
557 2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide).
558 (XVIII) MDMB-CHMICA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-
559 2-yl)-1-(cyclohexylmethyl)indole-3-carboxamide).
560 (XIX) PX-1 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-
561 fluoropentyl)indole-3-carboxamide).



858828

562 (XX) PX-2 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(5-
563 fluoropentyl)indazole-3-carboxamide).

564 (XXI) PX-3 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-
565 (cyclohexylmethyl)indazole-3-carboxamide).

566 (XXII) PX-4 (N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1-(4-
567 fluorobenzyl)indazole-3-carboxamide).

568 (XXIII) MO-CHMINACA (N-(1-Methoxy-3,3-dimethyl-1-oxobutan-
569 2-yl)-1-(cyclohexylmethyl)indazole-3-carboxylate).

570 n. Cumylindolecarboxamides and Cumylindazolecarboxamides.—
571 Any compound containing a N-(2-phenylpropan-2-yl) indole
572 carboxamide or N-(2-phenylpropan-2-yl) indazole carboxamide
573 structure, with or without substitution on the indole or
574 indazole ring to any extent, whether or not substituted on the
575 phenyl ring of the cumyl group to any extent, including, but not
576 limited to:

577 (I) CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-pentylindole-3-
578 carboxamide).

579 (II) Fluoro CUMYL-PICA (N-(2-Phenylpropan-2-yl)-1-
580 (fluoropentyl)indole-3-carboxamide).

581 o. Other Synthetic Cannabinoids.—Any material, compound,
582 mixture, or preparation that contains any quantity of a
583 Synthetic Cannabinoid, as described in sub-subparagraphs a.-n.:

584 (I) With or without modification or replacement of a
585 carbonyl, carboxamide, alkylene, alkyl, or carboxylate linkage
586 between either two core rings, or linkage between a core ring
587 and group structure, with or without the addition of a carbon or
588 replacement of a carbon;

589 (II) With or without replacement of a core ring or group
590 structure, whether or not substituted on the ring or group



858828

591 structures to any extent; and

592 (III) Is a cannabinoid receptor agonist, unless
593 specifically excepted or unless listed in another schedule or
594 contained within a pharmaceutical product approved by the United
595 States Food and Drug Administration.

596 191. Substituted Cathinones.—Unless specifically excepted,
597 listed in another schedule, or contained within a pharmaceutical
598 product approved by the United States Food and Drug
599 Administration, any material, compound, mixture, or preparation,
600 including its salts, isomers, esters, or ethers, and salts of
601 isomers, esters, or ethers, whenever the existence of such salts
602 is possible within any of the following specific chemical
603 designations:

604 a. Any compound containing a 2-amino-1-phenyl-1-propanone
605 structure;

606 b. Any compound containing a 2-amino-1-naphthyl-1-propanone
607 structure; or

608 c. Any compound containing a 2-amino-1-thiophenyl-1-
609 propanone structure,

610

611 whether or not the compound is further modified:

612 (I) With or without substitution on the ring system to any
613 extent with alkyl, alkylthio, thio, fused alkylenedioxy, alkoxy,
614 haloalkyl, hydroxyl, nitro, fused furan, fused benzofuran, fused
615 dihydrofuran, fused tetrahydropyran, fused alkyl ring, or halide
616 substituents;

617 (II) With or without substitution at the 3-propanone
618 position with an alkyl substituent or removal of the methyl
619 group at the 3-propanone position;



858828

620 (III) With or without substitution at the 2-amino nitrogen
621 atom with alkyl, dialkyl, acetyl, or benzyl groups, whether or
622 not further substituted in the ring system; or

623 (IV) With or without inclusion of the 2-amino nitrogen atom
624 in a cyclic structure, including, but not limited to:

625 (A) Methcathinone.

626 (B) Ethcathinone.

627 (C) Methylone (3,4-Methylenedioxymethcathinone).

628 (D) 2,3-Methylenedioxymethcathinone.

629 (E) MDPV (3,4-Methylenedioxypyrovalerone).

630 (F) Methylmethcathinone.

631 (G) Methoxymethcathinone.

632 (H) Fluoromethcathinone.

633 (I) Methylethcathinone.

634 (J) Butylone (3,4-Methylenedioxy-alpha-
635 methylaminobutyrophenone).

636 (K) Ethylone (3,4-Methylenedioxy-N-ethylcathinone).

637 (L) BMDP (3,4-Methylenedioxy-N-benzylcathinone).

638 (M) Naphyrone (Naphthylpyrovalerone).

639 (N) Bromomethcathinone.

640 (O) Buphedrone (alpha-Methylaminobutyrophenone).

641 (P) Eutylone (3,4-Methylenedioxy-alpha-
642 ethylaminobutyrophenone).

643 (Q) Dimethylcathinone.

644 (R) Dimethylmethcathinone.

645 (S) Pentylone (3,4-Methylenedioxy-alpha-
646 methylaminovalerophenone).

647 (T) Pentedrone (alpha-Methylaminovalerophenone).

648 (U) MDPPP (3,4-Methylenedioxy-alpha-



858828

649 pyrrolidinopropiophenone) .
650 (V) MDPBP (3,4-Methylenedioxy-alpha-
651 pyrrolidinobutyrophenone) .
652 (W) MPPP (Methyl-alpha-pyrrolidinopropiophenone) .
653 (X) PPP (Pyrrolidinopropiophenone) .
654 (Y) PVP (Pyrrolidinovalerophenone) or
655 (Pyrrolidinopentiophenone) .
656 (Z) MOPPP (Methoxy-alpha-pyrrolidinopropiophenone) .
657 (AA) MPHP (Methyl-alpha-pyrrolidinohexanophenone) .
658 (BB) F-MABP (Fluoromethylaminobutyrophenone) .
659 (CC) Me-EABP (Methylethylaminobutyrophenone) .
660 (DD) PBP (Pyrrolidinobutyrophenone) .
661 (EE) MeO-PBP (Methoxypyrrrolidinobutyrophenone) .
662 (FF) Et-PBP (Ethylpyrrrolidinobutyrophenone) .
663 (GG) 3-Me-4-MeO-MCAT (3-Methyl-4-Methoxymethcathinone) .
664 (HH) Dimethylone (3,4-Methylenedioxy-N,N-
665 dimethylcathinone) .
666 (II) 3,4-Methylenedioxy-N,N-diethylcathinone.
667 (JJ) 3,4-Methylenedioxy-N-acetylcatinone.
668 (KK) 3,4-Methylenedioxy-N-acetylmethcathinone.
669 (LL) 3,4-Methylenedioxy-N-acetylethcathinone.
670 (MM) Methylbuphedrone (Methyl-alpha-
671 methylaminobutyrophenone) .
672 (NN) Methyl-alpha-methylaminohexanophenone.
673 (OO) N-Ethyl-N-methylcathinone.
674 (PP) PHP (Pyrrolidinohexanophenone) .
675 (QQ) PV8 (Pyrrolidinoheptanophenone) .
676 (RR) Chloromethcathinone.
677 (SS) 4-Bromo-2,5-dimethoxy-alpha-aminoacetophenone.



858828

678 192. Substituted Phenethylamines.—Unless specifically
679 excepted or unless listed in another schedule, or contained
680 within a pharmaceutical product approved by the United States
681 Food and Drug Administration, any material, compound, mixture,
682 or preparation, including its salts, isomers, esters, or ethers,
683 and salts of isomers, esters, or ethers, whenever the existence
684 of such salts is possible within any of the following specific
685 chemical designations, any compound containing a phenethylamine
686 structure, without a beta-keto group, and without a benzyl group
687 attached to the amine group, whether or not the compound is
688 further modified with or without substitution on the phenyl ring
689 to any extent with alkyl, alkylthio, nitro, alkoxy, thio,
690 halide, fused alkylenedioxy, fused furan, fused benzofuran,
691 fused dihydrofuran, or fused tetrahydropyran substituents,
692 whether or not further substituted on a ring to any extent, with
693 or without substitution at the alpha or beta position by any
694 alkyl substituent, with or without substitution at the nitrogen
695 atom, and with or without inclusion of the 2-amino nitrogen atom
696 in a cyclic structure, including, but not limited to:
697 a. 2C-B (4-Bromo-2,5-dimethoxyphenethylamine).
698 b. 2C-E (4-Ethyl-2,5-dimethoxyphenethylamine).
699 c. 2C-T-4 (4-Isopropylthio-2,5-dimethoxyphenethylamine).
700 d. 2C-C (4-Chloro-2,5-dimethoxyphenethylamine).
701 e. 2C-T (4-Methylthio-2,5-dimethoxyphenethylamine).
702 f. 2C-T-2 (4-Ethylthio-2,5-dimethoxyphenethylamine).
703 g. 2C-T-7 (4-(n)-Propylthio-2,5-dimethoxyphenethylamine).
704 h. 2C-I (4-Iodo-2,5-dimethoxyphenethylamine).
705 i. 2C-D (4-Methyl-2,5-dimethoxyphenethylamine).
706 j. 2C-H (2,5-Dimethoxyphenethylamine).



- 858828
- 707 k. 2C-N (4-Nitro-2,5-dimethoxyphenethylamine) .
708 l. 2C-P (4-(n)-Propyl-2,5-dimethoxyphenethylamine) .
709 m. MDMA (3,4-Methylenedioxymethamphetamine) .
710 n. MBDB (Methylbenzodioxolylbutanamine) or (3,4-
711 Methylenedioxy-N-methylbutanamine) .
712 o. MDA (3,4-Methylenedioxymphetamine) .
713 p. 2,5-Dimethoxyamphetamine.
714 q. Fluoroamphetamine.
715 r. Fluoromethamphetamine.
716 s. MDEA (3,4-Methylenedioxy-N-ethylamphetamine) .
717 t. DOB (4-Bromo-2,5-dimethoxyamphetamine) .
718 u. DOC (4-Chloro-2,5-dimethoxyamphetamine) .
719 v. DOET (4-Ethyl-2,5-dimethoxyamphetamine) .
720 w. DOI (4-Iodo-2,5-dimethoxyamphetamine) .
721 x. DOM (4-Methyl-2,5-dimethoxyamphetamine) .
722 y. PMA (4-Methoxyamphetamine) .
723 z. N-Ethylamphetamine.
724 aa. 3,4-Methylenedioxy-N-hydroxyamphetamine.
725 bb. 5-Methoxy-3,4-methylenedioxymphetamine.
726 cc. PMMA (4-Methoxymethamphetamine) .
727 dd. N,N-Dimethylamphetamine.
728 ee. 3,4,5-Trimethoxyamphetamine.
729 ff. 4-APB (4-(2-Aminopropyl)benzofuran) .
730 gg. 5-APB (5-(2-Aminopropyl)benzofuran) .
731 hh. 6-APB (6-(2-Aminopropyl)benzofuran) .
732 ii. 7-APB (7-(2-Aminopropyl)benzofuran) .
733 jj. 4-APDB (4-(2-Aminopropyl)-2,3-dihydrobenzofuran) .
734 kk. 5-APDB (5-(2-Aminopropyl)-2,3-dihydrobenzofuran) .
735 ll. 6-APDB (6-(2-Aminopropyl)-2,3-dihydrobenzofuran) .



858828

736 mm. 7-APDB (7-(2-Aminopropyl)-2,3-dihydrobenzofuran).
737 nn. 4-MAPB (4-(2-Methylaminopropyl)benzofuran).
738 oo. 5-MAPB (5-(2-Methylaminopropyl)benzofuran).
739 pp. 6-MAPB (6-(2-Methylaminopropyl)benzofuran).
740 qq. 7-MAPB (7-(2-Methylaminopropyl)benzofuran).
741 rr. 5-EAPB (5-(2-Ethylaminopropyl)benzofuran).
742 ss. 5-MAPDB (5-(2-Methylaminopropyl)-2,3-
743 dihydrobenzofuran),
744
745 which does not include phenethylamine, mescaline as described in
746 subparagraph 20., substituted cathinones as described in
747 subparagraph 191., N-Benzyl phenethylamine compounds as
748 described in subparagraph 193., or methamphetamine as described
749 in subparagraph (2)(c)5.
750 193. N-Benzyl Phenethylamine Compounds.—Unless specifically
751 excepted or unless listed in another schedule, or contained
752 within a pharmaceutical product approved by the United States
753 Food and Drug Administration, any material, compound, mixture,
754 or preparation, including its salts, isomers, esters, or ethers,
755 and salts of isomers, esters, or ethers, whenever the existence
756 of such salts is possible within any of the following specific
757 chemical designations, any compound containing a phenethylamine
758 structure without a beta-keto group, with substitution on the
759 nitrogen atom of the amino group with a benzyl substituent, with
760 or without substitution on the phenyl or benzyl ring to any
761 extent with alkyl, alkoxy, thio, alkylthio, halide, fused
762 alkylenedioxy, fused furan, fused benzofuran, or fused
763 tetrahydropyran substituents, whether or not further substituted
764 on a ring to any extent, with or without substitution at the



858828

765 alpha position by any alkyl substituent, including, but not
766 limited to:

767 a. 25B-NBOMe (4-Bromo-2,5-dimethoxy-[N-(2-
768 methoxybenzyl)phenethylamine].

769 b. 25B-NBOH (4-Bromo-2,5-dimethoxy-[N-(2-
770 hydroxybenzyl)phenethylamine].

771 c. 25B-NBF (4-Bromo-2,5-dimethoxy-[N-(2-
772 fluorobenzyl)phenethylamine].

773 d. 25B-NBMD (4-Bromo-2,5-dimethoxy-[N-(2,3-
774 methylenedioxybenzyl)phenethylamine].

775 e. 25I-NBOMe (4-Iodo-2,5-dimethoxy-[N-(2-
776 methoxybenzyl)phenethylamine].

777 f. 25I-NBOH (4-Iodo-2,5-dimethoxy-[N-(2-
778 hydroxybenzyl)phenethylamine].

779 g. 25I-NBF (4-Iodo-2,5-dimethoxy-[N-(2-
780 fluorobenzyl)phenethylamine].

781 h. 25I-NBMD (4-Iodo-2,5-dimethoxy-[N-(2,3-
782 methylenedioxybenzyl)phenethylamine].

783 i. 25T2-NBOMe (4-Methylthio-2,5-dimethoxy-[N-(2-
784 methoxybenzyl)phenethylamine].

785 j. 25T4-NBOMe (4-Isopropylthio-2,5-dimethoxy-[N-(2-
786 methoxybenzyl)phenethylamine].

787 k. 25T7-NBOMe (4-(n)-Propylthio-2,5-dimethoxy-[N-(2-
788 methoxybenzyl)phenethylamine].

789 l. 25C-NBOMe (4-Chloro-2,5-dimethoxy-[N-(2-
790 methoxybenzyl)phenethylamine].

791 m. 25C-NBOH (4-Chloro-2,5-dimethoxy-[N-(2-
792 hydroxybenzyl)phenethylamine].

793 n. 25C-NBF (4-Chloro-2,5-dimethoxy-[N-(2-



858828

794 fluorobenzyl)]phenethylamine).

795 o. 25C-NBMD (4-Chloro-2,5-dimethoxy-[N-(2,3-

796 methylenedioxybenzyl)]phenethylamine).

797 p. 25H-NBOMe (2,5-Dimethoxy-[N-(2-

798 methoxybenzyl)]phenethylamine).

799 q. 25H-NBOH (2,5-Dimethoxy-[N-(2-

800 hydroxybenzyl)]phenethylamine).

801 r. 25H-NBF (2,5-Dimethoxy-[N-(2-

802 fluorobenzyl)]phenethylamine).

803 s. 25D-NBOMe (4-Methyl-2,5-dimethoxy-[N-(2-

804 methoxybenzyl)]phenethylamine),

805

806 which does not include substituted cathinones as described in

807 subparagraph 191.

808 194. Substituted Tryptamines.—Unless specifically excepted

809 or unless listed in another schedule, or contained within a

810 pharmaceutical product approved by the United States Food and

811 Drug Administration, any material, compound, mixture, or

812 preparation containing a 2-(1H-indol-3-yl)ethanamine, for

813 example tryptamine, structure with or without mono- or di-

814 substitution of the amine nitrogen with alkyl or alkenyl groups,

815 or by inclusion of the amino nitrogen atom in a cyclic

816 structure, whether or not substituted at the alpha position with

817 an alkyl group, whether or not substituted on the indole ring to

818 any extent with any alkyl, alkoxy, halo, hydroxyl, or acetoxy

819 groups, including, but not limited to:

820 a. Alpha-Ethyltryptamine.

821 b. Bufotenine.

822 c. DET (Diethyltryptamine).



858828

- 823 d. DMT (Dimethyltryptamine) .
824 e. MET (N-Methyl-N-ethyltryptamine) .
825 f. DALT (N,N-Diallyltryptamine) .
826 g. EiPT (N-Ethyl-N-isopropyltryptamine) .
827 h. MiPT (N-Methyl-N-isopropyltryptamine) .
828 i. 5-Hydroxy-AMT (5-Hydroxy-alpha-methyltryptamine) .
829 j. 5-Hydroxy-N-methyltryptamine.
830 k. 5-MeO-MiPT (5-Methoxy-N-methyl-N-isopropyltryptamine) .
831 l. 5-MeO-AMT (5-Methoxy-alpha-methyltryptamine) .
832 m. Methyltryptamine.
833 n. 5-MeO-DMT (5-Methoxy-N,N-dimethyltryptamine) .
834 o. 5-Me-DMT (5-Methyl-N,N-dimethyltryptamine) .
835 p. 5-MeO-DiPT (5-Methoxy-N,N-Diisopropyltryptamine) .
836 q. DiPT (N,N-Diisopropyltryptamine) .
837 r. DPT (N,N-Dipropyltryptamine) .
838 s. 4-Hydroxy-DiPT (4-Hydroxy-N,N-diisopropyltryptamine) .
839 t. 5-MeO-DALT (5-Methoxy-N,N-Diallyltryptamine) .
840 u. 4-AcO-DMT (4-Acetoxy-N,N-dimethyltryptamine) .
841 v. 4-AcO-DiPT (4-Acetoxy-N,N-diisopropyltryptamine) .
842 w. 4-Hydroxy-DET (4-Hydroxy-N,N-diethyltryptamine) .
843 x. 4-Hydroxy-MET (4-Hydroxy-N-methyl-N-ethyltryptamine) .
844 y. 4-Hydroxy-MiPT (4-Hydroxy-N-methyl-N-
845 isopropyltryptamine) .
846 z. Methyl-alpha-ethyltryptamine.
847 aa. Bromo-DALT (Bromo-N,N-diallyltryptamine) ,
848
849 which does not include tryptamine, psilocyn as described in
850 subparagraph 34., or psilocybin as described in subparagraph 33.
851 195. Substituted Phenylcyclohexylamines.—Unless



858828

specifically excepted or unless listed in another schedule, or contained within a pharmaceutical product approved by the United States Food and Drug Administration, any material, compound, mixture, or preparation containing a phenylcyclohexylamine structure, with or without any substitution on the phenyl ring, any substitution on the cyclohexyl ring, any replacement of the phenyl ring with a thiophenyl or benzothiophenyl ring, with or without substitution on the amine with alkyl, dialkyl, or alkoxy substituents, inclusion of the nitrogen in a cyclic structure, or any combination of the above, including, but not limited to:

- a. BTCP (Benzothiophenylcyclohexylpiperidine) or BCP (Benocyclidine) .
- b. PCE (N-Ethyl-1-phenylcyclohexylamine) (Ethylamine analog of phencyclidine) .
- c. PCPY (N-(1-Phenylcyclohexyl)-pyrrolidine) (Pyrrolidine analog of phencyclidine) .
- d. PCPr (Phenylcyclohexylpropylamine) .
- e. TCP (1-[1-(2-Thienyl)-cyclohexyl]-piperidine) (Thiophene analog of phencyclidine) .
- f. PCEEA (Phenylcyclohexyl(ethoxyethylamine)) .
- g. PCMPA (Phenylcyclohexyl(methoxypropylamine)) .
- h. Methoxetamine.
- i. 3-Methoxy-PCE ((3-Methoxyphenyl)cyclohexylethylamine) .
- j. Bromo-PCP ((Bromophenyl)cyclohexylpiperidine) .
- k. Chloro-PCP ((Chlorophenyl)cyclohexylpiperidine) .
- l. Fluoro-PCP ((Fluorophenyl)cyclohexylpiperidine) .
- m. Hydroxy-PCP ((Hydroxyphenyl)cyclohexylpiperidine) .
- n. Methoxy-PCP ((Methoxyphenyl)cyclohexylpiperidine) .
- o. Methyl-PCP ((Methylphenyl)cyclohexylpiperidine) .



858828

881 p. Nitro-PCP ((Nitrophenyl)cyclohexylpiperidine).
882 q. Oxo-PCP ((Oxophenyl)cyclohexylpiperidine).
883 r. Amino-PCP ((Aminophenyl)cyclohexylpiperidine).
884 196. W-15, 4-chloro-N-[1-(2-phenylethyl)-2-
885 piperidinylidene]-benzenesulfonamide.
886 197. W-18, 4-chloro-N-[1-[2-(4-nitrophenyl)ethyl]-2-
887 piperidinylidene]-benzenesulfonamide.
888 198. AH-7921, 3,4-dichloro-N-[1-
889 (dimethylamino)cyclohexyl]methyl]-benzamide.
890 199. U47700, trans-3,4-dichloro-N-[2-
891 (dimethylamino)cyclohexyl]-N-methyl-benzamide.
892 200. MT-45, 1-cyclohexyl-4-(1,2-diphenylethyl)-piperazine,
893 dihydrochloride.

894

895

896 ===== D I R E C T O R Y C L A U S E A M E N D M E N T =====

897 And the directory clause is amended as follows:

898 Delete lines 24 - 26

899 and insert:

900 Section 1. Paragraph (c) of subsection (1) of section
901 893.03, Florida Statutes, is amended to read:

902

903 ===== T I T L E A M E N D M E N T =====

904 And the title is amended as follows:

905 Delete lines 5 - 11

906 and insert:

907 United States Food and Drug Administration for certain
908 use; amending s. 893.13, F.S.; providing